ArticleCancer science2026
Secondary Lower-Body Sarcomas in Cervical Cancer Survivors Following Surgery, Radiotherapy, or Both: A Population-Based Study.
Article in Cancer science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Design, Synthesis and Antitumor Activity Evaluation in Vitro of Novel 1,6-Naphthyridine Derivatives.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026Article
- Secondary Lower-Body Sarcomas in Cervical Cancer Survivors Following Surgery, Radiotherapy, or Both: A Population-Based Study.Cancer science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Secondary sarcomas in cervical cancer survivors are understudied. We investigated the incidence and subtypes of secondary sarcomas by treatment modalities, the prognosis of secondary sarcomas, and whether surgery plus radiotherapy increases angiosarcoma incidence. This population-based retrospective cohort study analyzed Osaka Cancer Registry data on women aged 20-84 years diagnosed with cervical cancer (1980-2015), treated with surgery, radiotherapy, or both. Patients with distant metastases, survival time < 1 year, or missing data were excluded. We included 7591 patients with invasive cancer treated with surgery, 3882 with radiotherapy, and 4090 with surgery plus radiotherapy and 13,205 with carcinoma in situ treated with surgery. We assessed the first lower-body sarcoma occurrence ≥ 1 year post-diagnosis. Sarcomas developed in 6 patients treated with surgery (0 angiosarcomas), 10 with radiotherapy (1 angiosarcoma), and 19 with surgery plus radiotherapy (9 angiosarcomas). At 10 years, the cumulative incidence was 0.083% (95% confidence interval [CI], 0.024%-0.24%) for radiotherapy and 0.21% (95% CI, 0.10%-0.41%) for surgery plus radiotherapy, higher than that for surgery (invasive, 0.013%; in situ, 0.028%) (p < 0.001). Angiosarcoma incidence was higher with surgery plus radiotherapy (0.080%; 95% CI, 0.023%-0.23%) than with radiotherapy (0.028%; 95% CI, 0.003%-0.16%) (p = 0.029). Among patients diagnosed with sarcoma after radiotherapy or surgery plus radiotherapy, the 1-year overall survival rate was 33.3% (95% CI, 19.6%-56.8%). Radiotherapy, alone or combined with surgery, increased secondary lower-body sarcoma incidence compared with surgery. To our knowledge, this is the first population-based study to suggest that surgery plus radiotherapy is associated with angiosarcoma in cervical cancer survivors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.